On behalf of the Board of Directors, management, and employees of Outlook Therapeutics, I want to extend my deepest gratitude ...

Outlook Therapeutics ( ($OTLK) ) has provided an update. On January 31, 2025, Outlook Therapeutics entered into a Securities Purchase Agreement ...

ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United ...

ISELIN, N.J. - Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company with a current market capitalization of $50.3 million, announced the appointment of Faisal G. Sukhtian as ...

Outlook Therapeutics (OTLK) announced the presentation of data from NORSE EIGHT at the Hawaiian Eye and Retina 2025 Meeting being held January ...

For more information about Webull, visit www.webull.com. About Outlook Therapeutics, Inc. Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ...

ISELIN, N.J. - Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company with a current market capitalization of $50.3 million, announced the appointment of Faisal G. Sukhtian as Chairman ...

On Thursday, Outlook Therapeutics, Inc. (NASDAQ:OTLK) completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT evaluating ONS-5010 in wet age-related macular ...

For more information about Webull, visit www.webull.com. About Outlook Therapeutics, Inc. Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ...